EFFICACY OF L-BETARGIN APLICATION IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC PANCREATITIS
DOI:
https://doi.org/10.11603/1811-2471.2021.v.i1.12002Keywords:
diabetes mellitus type 2, chronic pancreatitis, treatment, L-BetarginAbstract
Currently both diabetes mellitus (DM) and chronic pancreatitis (CP) pose a serious medical and social problem due to their increasing prevalence.
The aim – to research the clinical and laboratory efficacy of amino acid complex L-Betargin application in patients with type 2 diabetes and CP.
Material and Methods. 76 patients with type 2 diabetes and CP were examined and divided into two groups depending on the prescribed treatment. Group І (n=40) of the examined patients received only basic treatment (BT); Group ІІ (n=36) of the examined patients was prescribed the amino acid complex L-Betargin 10 ml three times a day for one month in addition to basic treatment. All examined patients underwent general clinical investigations and tested for vitamin supply and homocysteine levels.
Results. The therapy proved more efficient in terms of the dynamics of clinical manifestations in Group II patients, who additionally received the amino acid complex L-Betargin. Moreover, dyspepsia in Group II patients decreased 4.7 times as compared to 2.6 times (р<0.01) decrease in Group I. The administration of the amino acid complex in addition to BT contributed to a more pronounced positive dynamics in carbohydrate metabolism in the examined patients. There was a statistically significant decrease in the level of HbA1c (up to 6.02±0.16 %), insulin (up to 11.33±0.84 U/L), C-peptide (up to 6.14±0.50 ng/mL), insulin resistance index (НОМА-IR) (up to 4.08±0.26) mostly in Group II patients. The additional L-Betargin administration also leads to a statistically significant decrease in the levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (р<0.05) and an increase of B vitamins, resulting in a homocysteine decrease in patients with type 2 diabetes and CP.
Conclusions. Complex therapy with L-Betargin is an efficient method for the correction of clinical and laboratory disorders (indicators of lipid and carbohydrate metabolism, vitamin supply and serum homocysteine levels) in patients with type 2 diabetes and CP.
References
Davydchyk, E.V., Snezhitskiy, V.A., & Nikonova, L.V. (2015). Vzaimosvyaz gipergomotsisteiniemii s ishemichieskoi boleznyu serdtsa i sakharnym diabietom [Relationship of hyperhomocysteinemia with coronary heart disease and diabetes mellitus]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta – Journal of Grodno State Medical University, 1 (49), 9-15 [in Russian].
Fadieienko, H.D., & Chernyshov, V.A. (2011). Urazhennia hastroduodenalnoi dilianky u khvorykh na tsukrovyi diabet: kliniko-populyatsiini aspekty [Defeat of the gastroduodenal region in patients with diabetes mellitus: clinical and population aspects]. Liky Ukrainy – Medicines of Ukraine, 7 (153), 48-50 [in Ukrainian].
Huhlina, O.S., Dudka, I.V., Dudka, T.V., & Smandich, V.S. (2020). Klinichna efektyvnist preparatu Antral® u khvorykh na khronichnyi pankreatyt [Clinical efficacy of Antral® in patients with chronic pancreatitis]. Zdorovia Ukrayiny – Health of Ukraine, 3, 17 [in Ukrainian].
Kocaba, Yu.Ya., & Babinec, L.S. (2018). Aktualni aspekty zastosuvannia probiotykiv pry dysbiozi tovstoi kyshky [Topical aspects of the use of probiotics in colonic dysbiosis]. Simeyna medytsyna – Family Medicine, 4 (78), 85-87 [in Ukrainian].
Larin, A.S., & Tkach, S.M. (2016). Patogeneticheskaya rol kishechnogo disbioza v razvitii ozhireniya, insulinorezistentnosti i sakharnogo diabeta 2 tipa [Pathogenetic role of intestinal dysbiosis in the development of obesity, insulin resistance and type 2 diabetes mellitus]. Zdorovia Ukrainy – Health of Ukraine, 2 (40), 20-21 [in Russian].
Stepanov, Yu.M. (2016). Noveyshiye tekhnologii v teoreticheskoy i prakticheskoy gastroenterologii [The newest technologies in theoretical and practical gastroenterology]. Zdorovia Ukrainy – Health of Ukraine, 13-14 (386-387), 20-21 [in Russian].
(2012). Ministerstvo okhorony zdorovia Ukrainy. Unifikovanyi klinichnyi protokol pervynnoi ta vtorynnoi (spetsializovanoi) medychnoi dopomohy: tsukrovyi diabet 2 typu. Nakaz Ministerstva okhorony zdorovia Ukrainy [Ministry of Health of Ukraine. Unified clinical protocol for primary and secondary (specialized) care: type 2 diabetes mellitus. Order of the Ministry of Health of Ukraine], 1118, 118 [in Ukrainian].
(2012). Ministerstvo okhorony zdorovia Ukrainy. Adaptovana klinichna nastanova, zasnovana na dokazakh: tsukrovyi diabet 2 typu. Nakaz Ministerstva okhorony zdorovia Ukrainy [Ministry of Health of Ukraine. Type 2 diabetes mellitus. Adapted clinical guideline based on evidence. Order of the Ministry of Health of Ukraine]., 1118, 343 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
